[A18-83] Ezetimibe for the prevention of cardiovascular Events - Rapid report

Last updated 05.09.2019

Project no.:

Commission awarded on 27.11.2018 by the Federal Joint Committee (G-BA).

Report type:
Rapid report

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


The present version 2.0 of 3 September 2019 replaces version 1.0 of the rapid report of 28 June 2019. There have been changes in the risk of bias for the outcome “serious cardiovascular events”.


Ezetimibe reduces the risk of heart attacks and strokes

Given in addition to statin therapy, ezetimibe has a preventive effect in patients with CHD and acute coronary syndrome


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.